Granules India Ltd Share Price & Stock Analysis

Granules India Ltd (BSE: 532482) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹20,836 Cr, it ranks #361 by market cap among the 6,197 Indian listed companies on FinBizNet, and #16 of 86 in Medicinal Chemicals and Botanical Products. At ₹814.00 (as of 16 Nov 2026), the share price is 11.9% below its 52-week high of ₹923.65 and 53.6% above its 52-week low of ₹529.85. The share price is up 47.3% over one year and down 5.2% over three months.

Key Metrics

Current Price₹814.00
Market Cap₹20,836 Cr
BSE Code532482
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio34.3
Return on Equity13.52%
Return on Assets7.98%
52-Week Range₹529.85 – ₹923.65
1-Year Price Change+47.3%
3-Month Price Change-5.2%
Beta (1Y)0.35
Dividend Yield0.21%
HeadquartersHyderabad, Telangana
Websitewww.granulesindia.com

Latest Quarterly Results — Q2 FY27

Revenue₹1,560 Cr
Net Profit₹182 Cr
Net Margin11.7%
EPS (Basic)₹7.22
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Granules India Ltd Quarterly Revenue and Profit Trend

Granules India Ltd reported revenue of ₹1,560 Cr in Q2 FY27, up 20.3% from ₹1,297 Cr in Q2 FY26 and up 5.6% from ₹1,477 Cr in Q1 FY27. It posted a net profit of ₹182 Cr for the quarter, against a net profit of ₹131 Cr in Q2 FY26 (up 39.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,197 Cr (Q4 FY25) to ₹1,560 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹1,560 Cr₹182 Cr11.7%
Q1 FY27₹1,477 Cr₹180 Cr12.2%
Q4 FY26₹1,471 Cr₹202 Cr13.7%
Q3 FY26₹1,388 Cr₹150 Cr10.8%
Q2 FY26₹1,297 Cr₹131 Cr10.1%
Q1 FY26₹1,210 Cr₹113 Cr9.3%
Q4 FY25₹1,197 Cr₹152 Cr12.7%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 37.39% of Granules India Ltd's shares as of Sept 2026, against 38.82% in Dec 2025 (−1.43 percentage points). Delivery averaged 47.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Granules India Ltd

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating

Products and Services

1. Manufacture of Pharmaceuticals-This segment offers pharmaceutical products, including ingredients and intermediaries. 2. Active Pharmaceutical Ingredients (API's)-This segment engages in the production and sale of active pharmaceutical ingredients, including metformin, methocarbamol, guaifenesin, phenazopyridine, and paracetamol, or acetaminophen. 3. Pharmaceutical Formulation Intermediates (PFI's)-This segment engages in the production and sale of pharmaceutical formulation intermediates.

Business Segments

1. Pharmaceutical Products-100%

Granules India Ltd vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Granules India Ltd₹20,836 Cr34.313.52%₹1,560 Cr+47.3%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Granules India Ltd?

Granules India Ltd is trading at ₹814.00, with a market capitalisation of ₹20,836 Cr.

Which sector does Granules India Ltd belong to?

Granules India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Granules India Ltd?

Granules India Ltd has a P/E of 34.3 and a return on equity of 13.52%.

What is the stock symbol of Granules India Ltd?

Granules India Ltd is listed on the BSE under the scrip code 532482.

How has Granules India Ltd's share price moved over the past year?

Granules India Ltd's share price is up 47.3% over one year and down 5.2% over three months. Its 52-week range is ₹529.85 to ₹923.65.

What were Granules India Ltd's latest quarterly results?

In Q2 FY27, Granules India Ltd reported revenue of ₹1,560 Cr and net profit of ₹182 Cr, with basic EPS of ₹7.22 (consolidated, parsed from the company's exchange filing).

How have Granules India Ltd's revenue and profit changed over the past year?

Granules India Ltd reported revenue of ₹1,560 Cr in Q2 FY27, up 20.3% from ₹1,297 Cr in Q2 FY26 and up 5.6% from ₹1,477 Cr in Q1 FY27.

What is the promoter holding in Granules India Ltd?

Promoters held 37.39% of Granules India Ltd's shares as of Sept 2026, against 38.82% in Dec 2025 (−1.43 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.